Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hormonal contraceptive product

a technology of hormones and products, applied in the field of hormone-based contraceptives, can solve the problems of sequential products used in substitution therapy that are particularly unsuitable for contraception, and are unsuitable for ovulation inhibition

Inactive Publication Date: 2005-01-06
HESCH ROLF DIETER
View PDF6 Cites 54 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This approach achieves high contraceptive reliability, suppresses ovulation and menstruation, reduces side effects, and lowers the risk of breast cancer by maintaining hormonal equilibrium and minimizing hormone fluctuations, suitable for various administration forms.

Problems solved by technology

Only in the case of substitution products in the menopause of older women have hormones been administered throughout the cycle, e.g. in the sequence 10 days estrogen product, 11 days combination of estrogen and gestagen product, 7 days estrogen product, 7 days estrogen product in a particularly low dosage, but said substitution products are unsuitable for ovulation inhibition.
The sequential products used in substitution therapy are in particular unsuitable for contraception because the natural estradiol does not prevent ovulation in the dosage administered and the phase in which gestagen is administered is too short, being only 11 days.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0053] For contraceptive treatment use was made of a product which per daily unit in table form contained 5 μg of ethinyl estradiol and 2 mg of norethisterone acetate. It is noteworthy that norethisterone acetate can be used in a concentration range of 0.5 to 5 mg. The product was administered for 9 months and revealed a very good contraceptive reliability whilst completely suppressing the menstrual cycle with no side effects. Within the framework of the present investigation it was ensured that the test persons took the product daily, i.e. without any taking interval, over the entire aforementioned time period.

example 2

[0054] For contraceptive treatment use was made of a product which per daily unit in table form contains 0.5 mg of estriol and 2 mg of chlormadinone acetate. It is noteworthy that estriol can be used in a concentration range of 0.5 to 3 mg and chlormadinone acetate in a concentration range of 0.75 to 5 mg. The product was administered for 12 months without any taking interval. The mode of action corresponded to that of example 1.

example 3

[0055] For contraceptive treatment use was made of a product which in each daily unit in tablet form contained 0.5 mg of estradiol valerate and 2 mg of lynestrenol. It is noteworthy that estradiol valerate can be used in a concentration range of 0.5 to 5 mg and lynestrenol in a concentration range of 0.5 to 4.5 mg. The product was administered for 12 months without any taking interval. The mode of action corresponded to that of example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a hormonal contraceptive product having two hormonal components, an estrogen and a gestagen, and a method for the continuous suppression of the menstrual cycle by uninterrupted administration of the product of the invention.

Description

RELATED APPLICATIONS [0001] The application is a continuation of U.S. Application No. 09 / 508,648, filed Jun. 5, 2000, which is the U.S. National Phase under 35 U.S.C. §371 of International. Application PCT / DE98 / 02636, filed Sep. 11, 1998, which claims priority to German Application No. DE 19739916.9, filed Sep. 11, 1997.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention relates to a hormonal contraceptive product with two hormonal components, the use thereof and a hormonal contraception process. [0004] 2. Description of the Related Art [0005] Since hormonal contraceptives became available in the 1960's, a number of hormonal components have been investigated with regards to their suitability in the most varied administration diagrams. A fundamental subdivision into combination and sequential products is possible. [0006] For example, if the desired cycle time is 28 days, in the case of the known combination products administration takes place ove...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/56A61K31/565A61K31/57A61K45/06A61P5/24A61P15/18A61P19/10A61P35/00G06F17/00
CPCA61K31/565A61K31/57A61K45/06Y10S514/841Y10S514/843A61K2300/00A61P15/18A61P19/10A61P35/00A61P5/24
Inventor HESCH, ROLF-DIETER
Owner HESCH ROLF DIETER
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com